Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonova Holding AGFRA:PHBA -0.91%89 Peter Lynch Fair Value is €11.96 as of Jul. 18, 2026, which is 100% below its 10-year median of 3.00. GuruFocus rates FRA:PHBA with a GF Score™ of 89/100 and a GF Value™ of €52.94 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 153 Medical Devices & Instruments companies, Sonova Holding AG ranks worse than 653594.12% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Sonova Holding AG's PEG is 1. Sonova Holding AG's 5-Year TTM EBITDA Growth Rate is 6.04.
Sonova Holding AG's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €1.98. Therefore, the Peter Lynch Fair Value for today is €11.96.
As of today (2026-07-18), Sonova Holding AG's share price is €43.40. Sonova Holding AG's Peter Lynch fair value is €11.96. Therefore, Sonova Holding AG's Price to Peter Lynch Fair Value Ratio for today is 3.63.
The historical rank and industry rank for Sonova Holding AG's Peter Lynch Fair Value or its related term are showing as below:
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Sonova Holding AG was 4.06. The lowest was 1.96. And the median was 3.00.
FRA:PHBA's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.52 * Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Sonova Holding AG (FRA:PHBA) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 6.04 instead of 15 in this case.
Sonova Holding AG's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
43.40
/
11.96
=
3.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonova Holding AG Peter Lynch Fair Value Related Terms
Sonova Holding AG Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Sonova Holding AG's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHBA vs ABT, SYK, MDT: Peter Lynch Fair Value Comparison
For the Medical Devices subindustry, Sonova Holding AG's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonova Holding AG Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sonova Holding AG's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Sonova Holding AG's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sonova Holding AG's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €1.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of €11.96 mean?
Sonova Holding AG (FRA:PHBA) has a Peter Lynch Fair Value of €11.96 as of Jul. 18, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Sonova Holding AG and its competitors. This is 299% above median its historical median of 3.00. Over the past decade, Sonova Holding AG's Peter Lynch Fair Value has ranged from 1.96 to 4.06. According to the industry distribution chart, Sonova Holding AG ranks #999999 out of 153 companies in the Medical Devices & Instruments industry.
Is Sonova Holding AG's Peter Lynch Fair Value too high?
Sonova Holding AG's current Peter Lynch Fair Value of €11.96 is 299% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.96 to a high of 4.06. Based on the distribution chart, Sonova Holding AG ranks #999999 out of 153 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sonova Holding AG has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonova Holding AG's Peter Lynch Fair Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sonova Holding AG ranks #999999 out of 153 companies for Peter Lynch Fair Value. This places Sonova Holding AG in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.52. Historically, Sonova Holding AG's own Peter Lynch Fair Value has ranged from 1.96 to 4.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.52, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Sonova Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonova Holding AG's current Peter Lynch Fair Value is €11.96, which is 299% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonova Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Sonova Holding AG (FRA:PHBA) is currently considered Modestly Undervalued. The stock's GF Value™ is €52.94, compared to a current price of €43.40 — trading 18% below its estimated fair value. The current Peter Lynch Fair Value is €11.96, which is 299% above median its 10-year median of 3.00. Sonova Holding AG's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Sonova Holding AG (FRA:PHBA), the current Peter Lynch Fair Value is €11.96 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonova Holding AG (FRA:PHBA) Overvalued in 2026?
Based on GuruFocus' analysis, Sonova Holding AG stock appears to be undervalued.
The current stock price of €43.40 is trading 18% below its estimated GF Value™ of €52.94.
GuruFocus considers Sonova Holding AG to be Modestly Undervalued.
Key valuation signals for FRA:PHBA:
Peter Lynch Fair Value: €11.96 (299% above median its 10-year median of 3.00)
GF Value™: €52.94 vs. price of €43.40 (18% below fair value)
No single metric tells the full story. See the FRA:PHBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonova is one of the world's largest manufacturers and distributors of hearing aids. The company is based in Switzerland and distributes its products in more than 100 countries through its internal sales team and independent retailers. It also sells cochlear implants and audio technologies.
89GF Score
Get the complete analysis for FRA:PHBA
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHBA has been successfully added to your 
